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 Introduction 
 African countries, particularly the smaller ones, suffer from various 
disadvantages that prevent local producers from serving a substantial 
proportion of their domestic markets for pharmaceuticals. How to take 
care of these disadvantages to promote local production and to reduce 
dependence on imports is an important political and economic issue 
in Africa today. Most of the countries with developed industries have 
used foreign investments and technology in the process of their devel-
opment. Is a similar trend likely in Africa? Are foreign companies likely 
to invest there to undertake manufacturing of pharmaceuticals? Can 
they be induced to do so? The objective of this chapter is to understand 
the prospects for foreign direct investment (FDI) in the pharmaceutical 
industry in Sub-Saharan Africa, particularly in smaller countries such as 
Ghana. 
 The foreign firms which are active in Africa can be broadly classified 
between the multinational corporations (MNCs) and the Indian generic 
companies. These two types of firms are quite different in terms of back-
ground and behaviour, and in the next section some of these differences 
are briefly outlined. The environment for pharmaceutical production 
and manufacturing is changing quite rapidly, both in Africa and abroad, 
and that is having an impact on the behaviour of both the MNCs and 
the Indian companies. The chapter first focuses on the MNCs and 
discusses the implications for the pharmaceutical markets in Africa. It 
then focuses on the Indian companies. We will see in the discussion that 
follows that on their own initiative, Indian companies may not be very 
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keen to undertake investments for manufacturing in Africa. But given a 
conducive environment, they may not be averse to initiating manufac-
turing in Africa on a greater scale. The final section of the chapter takes 
up the case of Ghana, a relatively small African country. After a brief 
introduction to the structure of pharmaceutical market and industry in 
Ghana, the chapter analyses some policies which may be undertaken to 
promote local production, particularly in order to induce foreign firms 
to invest in Ghana. 
 MNCs, generics companies and the international 
pharmaceutical industry 
 Traditionally, pharmaceutical companies are classified between a small 
number of big MNCs that do research and development (R&D) for new 
drugs and aim to get these patented, and a large number of smaller 
generics companies that manufacture products that are not patented 
or products for which patents have expired. The MNCs are exception-
ally large in size. The head offices are located in developed countries, 
mainly in the US, the UK, Switzerland, France, and Germany. They 
operate all over the world. The largest pharmaceutical MNC, Novartis 
(headquarters: Basel, Switzerland) reported US$46 billion in pharma-
ceutical sales in 2013. Each of the other top five MNCs – Pfizer (US), 
Roche (Switzerland), Sanofi (France), Merck (US) and GlaxoSmithKline 
(UK) – individually had sales worth more than the entire pharmaceutical 
market of the Middle East and Africa in 2013. 1 
 The patent system and marketing power are at the root of the world-
wide dominance of the MNCs. Naturally, for the products patented by 
the MNCs, they enjoy a monopoly status. They also use an elaborate 
marketing infrastructure to maintain dominant market shares even after 
patents expire. Even when the product is protected through patents, the 
MNCs promote their drugs under brand names, that is, through trade-
marks, rather than under generic names, which are commonly used in 
scientific literature. They continue using these brand names and try to 
take advantage of continuing brand loyalty when generic companies 
enter the market after the expiry of patents. 
 Traditionally MNCs have relied for their growth on patented drugs, 
and have focussed mainly on the large developed country markets. 
The largest pharmaceutical market is in US (US$343 billion), and this 
together with Western Europe (US$241.4 billion) and Japan (US$129.5 
billion) accounted for about two-thirds of the global pharmaceutical 
market of US$1,052.1 billion in 2012 (BMI Espicom, 2013). 
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 Like most other countries in the world, India after independence 
initially recognized product patent protection in pharmaceuticals, and 
the MNCs dominated the Indian market too. However, the abolition of 
product patents in 1972 eliminated the monopoly status that the MNCs 
enjoyed until then. Indian firms started manufacturing and marketing 
the latest drugs and were able to dislodge the MNCs from their posi-
tion of dominance in the domestic market. India became self-reliant in 
drugs. The country furthermore emerged as a major player in the global 
pharmaceutical industry, receiving worldwide recognition as a low-cost 
producer of high-quality drugs. India now supplies medicines not only 
to other developing countries such as those in Africa but also to devel-
oped countries such as the United States. 
 The Indian pharmaceutical industry is highly heterogeneous. Most 
of the firms are small in size and operate only in the domestic market 
or in other developing countries. But some of the companies are large 
and not only compete with these small firms in these markets but also 
are active in regulated markets in developed countries. Two companies 
from India – Sun Pharmaceuticals (rank 48) and Ranbaxy (rank 50) – are 
among the 50 largest pharmaceutical companies in the world. 2 With 
the acquisition of Ranbaxy in 2014, Sun Pharmaceuticals will make 
a significant jump in the rankings. Other major Indian companies 
include Dr Reddys Laboratories, Cipla, Lupin, Glenmark and Cadila 
Healthcare. The larger Indian companies not only manufacture drugs 
in India and export these to different parts of the world. They have also 
started acquiring companies abroad to expand their manufacturing and 
marketing operations. 
 The changing marketing strategy of MNCs in Africa 
 Due to colonial or other links, some of the MNCs, for example 
GlaxoSmithKline (Glaxo as the firm then was known), had offices in 
some African countries. But as the MNCs started focusing more on 
the larger and more lucrative developed country markets, the African 
markets, especially in small countries, became less and less important 
for them and they started closing down their offices. Of course, their 
products were still available, but these imports were managed by their 
agents – local importers/distributors. 
 In recent years, however, the MNCs are returning to Africa and are 
focusing more on the subcontinent. Both push and pull factors are in 
operation. The most important push factor is that developed country 
markets have become less attractive, and the main pull factor is the 
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better growth prospects in Africa (Mckinsey and Company, 2013; 
Tempest, 2011). 
 The cost of developing new drugs has gone up, but the introduc-
tion of new patented drugs in the market has slowed down. Earlier, as 
mentioned above, because of the steady flow of new patented drugs, 
the MNCs focussed mainly on the large markets for patented medicines 
in high-income countries. But in view of the declining productivity of 
R&D, MNCs can no longer afford to ignore the generics markets. Their 
turn to generics markets includes not only the patent-expired markets 
in the high-income countries but also the generics markets in emerging 
economies. The centres of economic activity are changing, with most 
of the growth expected to come from emerging markets (Mckinsey and 
Company, 2013). 
 Among emerging markets, Africa is still relatively small. The combined 
size of the market of the top ten African countries is about US$14 
billion, compared to US$343 billion in the US and US$129 billion in 
Japan (Table 6.1). However, the future growth is expected to take place 
in emerging countries, including in Africa, rather than in the developed 
countries. It has been estimated that between 2012 and 2018, major 
developed country pharmaceutical markets will remain stagnant (as in 
Japan and the UK), increase marginally (as in the US), decline margin-
ally (as in Germany and France) and decline significantly (as in Italy and 
Spain). In contrast, the top ten African countries are expected to grow 
at 11% annually (Table 6.1). Quite understandably, therefore, while 
preparing their strategies for future, the MNCs are focusing more on the 
emerging countries, including in Africa. 
 The major drivers of growth in pharmaceutical markets in Africa have 
included increased disease burdens, particularly HIV/AIDS. The private 
markets have been expanded by developments in health insurance 
schemes, and some countries’ health systems have seen large invest-
ments in public health. Political stability and rapid economic develop-
ment, improving business climate, a maturing regulatory environment 
and increased confidence in generic products have all also contributed 
to market expansion (African Union and UNIDO, 2012; Mckinsey and 
Company, 2013). 
 The changes are having a variety of different impacts on the behav-
iour of the MNCs in Africa. The MNCs are no longer relying only on 
their agents. They have started opening offices and staffing these with 
their own employees. Marketing expenses for brand promotion have 
risen. To push up their sales they have also started offering credit facili-
ties. Another notable development is that the MNCs are toning up their 
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distribution networks. They have started using the services of special-
ized supply chain organizations such as Imperial Health Sciences. The 
latter has operations in South Africa, Kenya, Ghana, Nigeria and Malawi, 
where medicines are received, stored and distributed in countries across 
Africa. 
 Perhaps the most significant development of all is that MNCs have 
started introducing new brands to compete in the generic markets. As 
mentioned above, when MNCs market new patented drugs, they sell 
these in brand names and continue to do so even after the patents 
expire. The patented drugs in monopoly markets are high priced. For 
patent-expired products too, the MNCs participate in the higher end of 
the market that has more limited competition. Even after the patents 
expire, the firms typically continue to use the same brands and continue 
to charge a very high price. 
 This strategy on the part of the MNCs has, in fact, helped the Indian 
generic companies. The large Indian companies typically adopt the 
strategy of charging a price lower than that of the MNCs to enter and 
 Table 6.1  Anticipated trends in global pharmaceutical markets 
Country












China 82 164 12
Russia 22 39 10
India 16 28 10
Brazil 27 39 7
Africa** 14 26 11
Developed markets
US 343 360 1
Japan 129 129 0
Germany 49 47 –1
France 43 41 –1
UK 38 38 0
Canada 26 25 –1
Italy 28 22 –4
Spain 23 16 –6
 Note: * Compound annual rate of growth 
 ** South Africa, Algeria, Egypt, Morocco, Tunisia, Sudan, Nigeria, Libya, Ivory Coast and 
Kenya. 
 Source : Mckinsey and Company, 2013. 
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grow market share in the patent-expired products. Armed with lower 
prices and active brand promotion, Indian companies such as Cipla, 
Ranbaxy, Sun Pharmaceuticals, Cadila and Glenmark have been able to 
dominate the markets in many products. 
 Particularly for Sub-Saharan African countries, India is the predomi-
nant supplier. In Tanzania, for example, the Indian generics company 
Cipla was the second-largest company in the retail market in 2010 with 
a market share of 16%, next only to the local firm, Shelys (21% market 
share), and ahead of MNCs such as Novartis (10%) and GSK (6%). Among 
the other notable Indian participants are companies such as Ranbaxy 
(8%), Sun Pharmaceuticals, Unichem Laboratories, Cadila Glenmark 
and Ajanta Pharma (Frost and Sullivan, 2010: 151; 2012: 81–83). As 
in most African countries, local firms in Tanzania manufacture a rela-
tively simple list of formulations such as simple antibiotics, cough and 
cold preparations, analgesics antipyretics, sedatives, nutraceuticals, 
anthelmintics and anti-malarials (see Chapter 3; Chaudhuri et al., 2010). 
For technologically more sophisticated formulations, the competition is 
mainly between the MNCs and the Indian companies. 
 The MNCs are now increasingly trying to make their presence felt in 
these generic markets. They are reluctant to dilute their innovator brand 
by lowering the price to compete against generic products. There is a 
brand loyalty associated with innovator products and there is a price-
insensitive market segment where MNCs continue to sell despite high 
prices and despite the availability of cheaper generic products. To enlarge 
their market, the MNCs are introducing new brands and selling these at 
prices significantly lower than their innovator brands. The dual-brand 
strategy enables them to be present not only in the price-insensitive 
segment of the market but also in the price-sensitive segment. 
 The most active MNC in this game is GSK. The innovator brand for 
their anthelmintic drug, albendazole, is Zentel. They have introduced 
a new brand for the same product, named Alzental. Another example 
is the antibiotic amoxicillin/clavulanate. The GSK innovator brand is 
Augmentin. They also sell the same product in the brand name Clavulin 
to compete against similar-sounding generic brands such as, for example, 
Clavam of India’s generics company Alkem. These MNC generic brands 
are priced significantly below the innovator price, often 50% or less. 
These are still priced above the brands of generic companies. But with 
the price differential much smaller and their better reputation, the MNCs 
hope to prevent the slide in their sales in the generics markets. 
 Now that they have started competing on prices, the matter of costs 
has become important. Another important trend observed is that the 
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MNCs are trying to get their generic products manufactured in cheaper 
locations. The Ghanaian company LaGray has entered into an agree-
ment with Sandoz, the generic arm of Novartis. The former will manu-
facture products to be marketed in their brand names by the latter. 
India offers an even cheaper location. MNCs such as GSK, AstraZeneca 
and Abbott have entered into supply agreements with Indian compa-
nies such as Dr Reddys, Aurobindo, Cadila Healthcare and Torrent. 
Dr Reddys, for example, will supply about 100 branded formulations to 
GSK for marketing in different emerging markets including in Africa. 
These deals enable the MNCs to get access to low-cost reliable products 
without undergoing the lengthy process of getting regulatory approvals 
in different markets and without incurring any capital expenditure for 
setting up manufacturing plants. The Indian companies gain by having 
access to the formidable marketing resources of the MNCs (Chaudhuri, 
2012). 
 However, what these trends indicate is that although MNCs are 
targeting African markets, they are unlikely to make any significant 
investments to manufacture drugs in Africa, at least not in the near 
future. 
 Indian generic companies in the African market 
 European countries, mainly France, Germany and Switzerland, are 
the most important suppliers for some relatively large North African 
countries such as Algeria, Morocco and Egypt (UNCOMTRADE). But 
for Sub-Saharan Africa, India is the predominant supplier of medi-
cines. As Table 6.2 shows, in 2012 India contributed more than 50% 
of the formulations imports in Uganda and Mozambique and more 
than 40% in Nigeria, Ghana and Rwanda. Its share was also substan-
tial in countries such as Ethiopia, Tanzania and Zimbabwe. If we could 
exclude the imports of high-priced patented medicines and focus only 
on generics, India’s contribution to Africa would be much larger than 
Table 6.2 suggests. Where drugs are purchased from multiple sources, as 
for example for ARVs, India has turned out to be the dominant supplier, 
accounting for more than two-thirds of Africa’s imports (Chaudhuri, 
2008). 
 Indian generic companies exporting medicines to Africa can be clas-
sified into two broad categories: those which are active also in the regu-
lated markets in developed countries such as the United States, and those 
which are not yet present in these markets. The larger and more reputed 
companies belong to the first category. These more dynamic Indian 
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generic companies have been more interested in the patent-expired 
markets in high-income countries such as the US and in Europe because 
of the larger markets and better prices realized. Prices achieved are higher 
in these markets because regulatory requirements to enter these markets 
are stricter and so entry is more difficult. The Indian companies active 
in the African markets also primarily target the markets where entry 
barriers are higher and hence competition is less strong. These compa-
nies promote their products through brands and their main competitors 
are the MNCs (and also generics companies from other countries). As 
mentioned above, these companies often try to enter and grow in these 
markets by charging a price lower than that of the innovator MNC. The 
 Table 6.2  Indian share of pharmaceutical formulations imports into Africa, 
2012 
Country
 Total imports, 
















Côte d’Ivoire 259 19.1
Madagascar 49 18.9








Cabo Verde 8 1.3
Egypt 1,498 0.5
Total (25 countries) 8,139 13.7
 Source : Calculated from UNCOMTRADE database ( http://comtrade.un.org ). 
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smaller Indian companies are more active in over-the-counter medicines 
and in markets for simple products where they compete mainly against 
the local manufacturers and other smaller generic companies. 
 The changing composition of Indian companies 
 The composition of Indian generic companies is however changing in 
Africa. With improvements in the regulatory environment in Africa, 
the not so quality-conscious Indian companies are increasingly finding 
it difficult to operate there. Allegations have been made from time to 
time that some Indian companies have taken advantage of the regula-
tory environment in India and in Africa to export poor-quality drugs. In 
fact, it has been a very common complaint in Africa that India has not 
been taking initiatives to regulate the quality of drugs exported. This is 
now changing. Due to the efforts of the government in India and also 
some steps taken in some African countries, the quality standards have 
improved. Most African countries, for example, do not permit imports 
into their countries from India without a Certificate of Pharmaceutical 
Product (COPP). This is given by the drug control administration in 
India to units that qualify for the WHO-GMP standard. This standard is 
stricter than Schedule M, the Indian version of GMP, and hence exporters 
are required to satisfy higher standards than in the domestic market. 
 Like the MNCs, the more serious Indian players are also getting more 
involved in Africa. Here too both push and pull factors are in operation. 
An important push factor arises from the fact that earlier expectations 
of huge gains in the patent-expired markets in large markets such as 
in the United States have not materialized. Those markets have turned 
out to be very competitive, despite some value-added market segments 
where competition can be limited and where gains are still substantial. 3 
However, with the declining R&D productivity and a reduced flow of 
new patented drugs in the market, the MNCs are aggressively trying to 
make the entry of generic companies more difficult in these markets. 
 The better regulatory environment in Africa has improved the attrac-
tiveness of the market for the larger Indian companies and is acting as 
an important pull factor there. Perhaps more important is the antici-
pated future growth in the pharmaceutical market in Africa. The African 
market is still relatively small for Indian companies. Africa accounts 
for about 15% of India’s exports (Table 6.3). But Africa is an expanding 
market for India. The growth of India’s pharmaceutical exports has been 
quite spectacular, and Africa has been able to increase its share from 
about 10% in 1994–95 to 15% in 2011–12. The growth of the African 
market has in fact been faster than all other regions except America 
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(Table 6.3). In 1994–95, just Nigeria and Kenya accounted for about 
50% of India’s exports to Africa, and the share of top five countries was 
nearly three-quarters of the total. However India’s exports now are more 
diversified. Among the countries which are relatively more important 
are Ghana, Benin, Sudan, Angola, Malawi and Cameroon. 4 
 Are Indian companies likely to invest in manufacturing in Africa? 
 It is clear that Indian companies will continue to play a very active role 
in the African markets. Indeed, because of the factors mentioned above, 
they are likely to expand their operations there. Some Indian companies 
have already been actively involved in foreign direct investments (FDI) 
in Africa. Notable examples are Cadila in Ethiopia, Cipla in Uganda and 
South Africa and Ranbaxy in Nigeria. Other Indian companies too may 
be involved in the future in setting up manufacturing plants in Africa. 
But are Indian companies in general likely to be involved in any signifi-
cant scale in investing in Africa? R Modi, chief of the Indian company 
Cadila, mentioned during his presentation at the African Pharmaceutical 
Summit in Hammamet, Tunisia, on 23–24 September 2013 that profit 
has not been the main motivation for Cadila’s investments in Ethiopia. 
It is possible that beyond narrow financial reasons, some Indian compa-
nies will invest in Africa. But if Africa is to benefit in any significant 
way from Indian companies to further develop the industry there, what 
is required is more systematic investments. Unless Indian companies 
find Africa commercially attractive, it will be difficult to sustain such 
investments. 
 Table 6.3  India’s Pharmaceutical exports 
1994–95 1994–95 2011–12 2011–12
(Rs million) (%) (Rs million) (%)
Europe 10,663 42.4 90,964.35 29.6
America 3,661 14.6 90,147.29 29.3
Asia 7,941 31.6 77,886.87 25.3
Africa 2,676 10.7 45,280.45 14.7
Oceania 182 0.7 2,949.168 1.0
Others 0 0 368.29 0.1
Total 25,123 100 307,596.4 100.0
 Source : India’s Directorate General of Commercial Intelligence and Statistics (DGCI&S) 
trade data, accessed from the ‘India Trades’ database of the Centre for Monitoring Indian 
Economy. 
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 Unless the policy environment changes in Africa, the indications are 
that Indian companies in general will continue to find exporting a better 
option than investing in Africa. The main reasons are the following. 
 Perhaps most importantly, Indian companies essentially face a free 
trade regime in Africa. Some countries impose tariffs on imports of 
finished formulations. Some countries have a restricted list, as in Ghana, 
as discussed below. But in general, imports are not otherwise controlled 
or prohibited. This implies that from the Indian firms’ point of view, it 
is easier to export than to undertake direct investments. Export activity 
does not involve huge investment, nor is it risky. Lately, as just discussed, 
African countries are trying to improve their drug registration and regu-
latory systems, but traditionally it has been very easy to enter most of 
the African markets. 
 The most common model followed by Indian firms is for the Indian 
exporters to tie up with local importers/distributors. In some African 
countries, this trade is dominated by people of Indian origin, so that 
linking up with traders is not a difficult proposition in these countries. 
Again in comparison to China, the main competitor in Africa, India 
has the advantage of more exposure to the English language, which is 
understood and used in many African countries. The main role of the 
Indian company is therefore restricted to getting the product registered 
and manufacturing and supplying to local partners. This hardly requires 
much investment: Indian companies do not create separate plants for 
the African markets. They use their existing capacity – often excess 
capacity – for the purposes. It is also practically riskless. Many exporters 
insist on advance payment. Even where the medicines are supplied on 
credit, at worst the Indian company will lose money for that consign-
ment, and then they can stop supplying medicines in the future. 
 Investments abroad, on the other hand, involve more risks. It is very 
important for foreign investors to be assured of the safety of their invest-
ments. Africa is now politically much more stable. But foreign investors 
seem to expect some proactive steps on the part of the government to 
instill confidence that their money will be safe and that, if necessary, 
they can take money out of the country. There are also risks related to 
volatility of foreign exchange rates. Perhaps most important, the local 
partnerships required for direct investments carry higher risks. Export 
activities of Indian companies are carried out through local partners, as 
mentioned above, and in such cases the roles are clearly defined and risks 
are fewer. In case of joint ventures, however, the success of the company 
will depend much more on the local partners. The question of reliability 
of partners becomes more important in the case of investments abroad, 
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since substantial investments would be involved and it is not easy to get 
rid of undesirable partners. 
 It follows that it is still quite a challenge to undertake manufacturing 
activities in Africa. Most of these countries suffer from various disadvan-
tages, discussed in the preceding chapters. They include lack of technical 
know-how and trained manpower in the local African labour markets 
and the low levels of development of support industries including 
suppliers of APIs, other materials and machinery. Production costs may 
be higher than in India because input costs and utility costs are higher, 
and also because productivity may be lower. In some smaller countries, 
the market is considered too small for profitable operations. 5 It is there-
fore much easier for Indian companies to manufacture in India and then 
to serve the African markets through exports. 
 This current status and set of perceptions can however be changed 
through policy interventions. Left to themselves, foreign firms may not 
be keen to invest. But if proper conditions are created, if the above-
mentioned issues and factors are taken care of, then they might be 
induced to do so. If the experience of other countries is any guide, then 
neither the inflows of FDI nor the benefits from FDI result from a passive 
open-door FDI policy (Lall and Narula, 2004; Chang, 2004). What is 
required is an active industrial policy. 
 The last section of this chapter develops this argument for the case 
of Ghana. 6 It discusses how foreign firms can help to develop a local 
pharmaceutical industry, and how they can be induced to contribute to 
promote local production. 
 Ghana, industrial policy and foreign direct investment 
 Ghana is a relatively small African country. The size of its total formu-
lations market was estimated at about US$329 million in 2012 (BMI, 
2013: 16). There are about 38 pharmaceutical manufacturing units 
in Ghana of which about 20 are actively involved in manufacturing 
formulations. Only one company, LaGray, started manufacturing an API 
(erythromycin) for their own use in formulation manufacturing. Local 
production caters to about 30% of the market, with the remaining 70% 
of demand being met from imports. Some of the local firms, for example 
Kama and Ernest Chemists, are involved in both manufacturing and 
importing. 
 India is a major source of Ghanaian imports not only of formulations 
but also of the APIs and other materials required for the local production 
of formulations. Out of the 30% of the market which is supplied by local 
Foreign Firms and Local Production in Africa 115
manufacturers, 25% are over-the-counter (OTC) medications and the 
remaining 5% are simple prescription formulations. About two-thirds 
of drug purchase in Ghana are financed through out-of-pocket expendi-
ture, the remaining being financed through public procurement, donor-
funded purchases and reimbursement by the National Health Insurance 
scheme. Ghana has an elaborate drug distribution system dominated by 
importers/distributors/wholesalers. The branded generics segment of the 
market is large, and both imported products and locally manufactured 
generic products are sold as brands. Local manufacturers are actively 
involved in sales promotion, particularly for OTC items. 
 The Ghanaian government has put in place a number of policies 
that have helped the local industry to grow to attain its present status. 
Among these policies, one of the most important steps taken to promote 
the pharmaceutical industry was to ban the imports of finished formu-
lations of 14 widely used products including ampicillin, tetracycline, 
chlordiazepoxide, indomethacin, paracetamol, aspirin and diazepam. 
Domestic formulations manufacturing has also benefitted substantially 
from the industrial protection provided by combination of zero import 
duties on materials and machinery required for formulations production 
with 10% import duty on imports of finished formulations. Another 
important advantage that domestic formulations manufacturers have 
been enjoying was the refunding of the 15% VAT imposed on all mate-
rials and machinery required for formulations production. However, in 
2013, the government has withdrawn this benefit, as has also happened 
elsewhere (see Chapter 2). 
 Like other countries discussed in this book, Ghana also offers a 15% 
price preference for domestic suppliers in public procurement. This has 
also helped manufacturers, though the system has not always func-
tioned properly. Local manufacturers complain that the procurement 
system is not very transparent, and especially when the government 
buys at regional and local levels there is suspicion that the 15% advan-
tage is often not provided. The government does not reveal the prices at 
which it actually procures. Perhaps if such information is made public 
the situation will improve. 
 Industrial policy in Ghana 
 What can be done to further increase the share of local production 
in the Ghanaian domestic market? What is fundamentally impor-
tant for promoting an industry is to put in place policies to provide 
access to three key aspects of business activity: finance, technology and 
markets. 
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 This section first discusses the problems of finance and technology 
in the context of Ghana. It then explores the ways in which a policy of 
ensuring a larger market for local producers can prompt FDI to assist the 
development of the pharmaceutical industry in Africa. 
 Under the conditions in which they operate, the local firms hardly 
earn adequate profits to plough back into investments. Furthermore, the 
rate of interest charged by banks in Ghana is exorbitant, often exceeding 
30% per annum. As shown below, to set up Good Manufacturing 
Practice (GMP)-compliant manufacturing plants, to develop products 
for getting regulatory approval and for marketing these products, huge 
funds are required. Taking loans at such high interest rates is simply not 
a viable option, so that exploring other funding options is vital. The 
more resourceful foreign firms with access to diverse sources of funding 
offer one of the possible policy options. 
 Technology, furthermore, is a fundamental constraint in Africa today. 
When pharmaceutical manufacturing started in Ghana, technical 
requirements were simpler and technology was often arranged through 
informal channels. The promoters of local companies such as Amponsah 
Efah, LaGray and Pharmanova are themselves technologists, and they 
have used their knowledge and contacts to set up small-scale plants. But 
the technological scenario in recent years has changed fundamentally. 
Current requirements are significantly tougher. If local manufacturing 
in Ghana is to make a significant difference to the industry, then tech-
nical knowledge and expertise need to be available qualitatively and 
quantitatively on a big scale. 
 The first technological requirement is that the manufacturing plants 
need to be GMP compliant. To set up a GMP-compliant plant, signifi-
cant additional costs, particularly investment costs, have to be incurred. 
Moreover, the products manufactured need to be approved for marketing 
by the local drug control administration. The companies are required 
to undertake various types of studies (e.g. bioequivalence studies) and 
to generate data and submit dossiers to the drug control authorities. 
Marketing approval is granted after various types of review by the latter, 
including chemistry review, bioequivalence review and after-plant 
inspection. 
 The technical knowledge required to set up and run GMP-compliant 
plants and to develop products for getting regulatory approvals for 
marketing are not widely available in Ghana and other African coun-
tries. It is vitally important to arrange this if the local industry is to 
develop. 
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 A possible solution is to use the technological resources of foreign 
firms for the purpose. Manufacturing operations by Western MNCs are 
carried out in quite a different environment, while the situation in India 
is much closer to that in Africa. Pharmaceutical technical knowledge is 
furthermore highly diffused in India, so if Indian companies invest in 
Africa, then a major constraint will be lifted. 
 Furthermore, as Chapter 5 has emphasized, market access and serving 
the local market effectively are essential elements of business success. If 
the African governments can initiate policies to substantially limit the 
access of foreign firms to the domestic market, then Indian (or other 
foreign) companies will lose out unless they undertake investments 
in Africa to cater to that market. Where the loss is substantial, as in 
the cases of larger countries or regional markets, chances of FDI will be 
much higher. How can a country manage its domestic market to induce 
foreign firms to invest? 
 Policy makers in developing countries often are reluctant to impose 
import controls on the grounds that such an action may lead to short-
ages and/or lack of import competition may lead to higher prices. But 
this need not necessarily be the case, as Ghana shows. The products 
on its banned list are manufactured adequately in the country, and the 
country did not suffer from shortages after the policy was imposed. Lack 
of import competition has not resulted in higher prices. Importantly, 
import competition has been replaced by domestic competition, leading 
to competitive prices in the domestic market. 
 To explore the question of pricing further, Table 6.4 compares the 
retail prices of selected products in India and Ghana. The products 
include some of those which are manufactured in Ghana, for example 
ciprofloxacin, paracetamol, amlodipine, diazepam, metformin and 
also some of those that are not currently manufactured in Ghana, for 
example anastrazole, granisetron, losartan, rabeprazole and rosuvas-
tatin. As Table 6.4 shows, the extent of price differentials between India 
and Ghana is quite different, depending on whether these products 
are manufactured in Ghana or not. For the products not manufactured 
in Ghana, the price differentials are significantly larger. For the prod-
ucts manufactured in Ghana, not only is the price differential much 
narrower – less than 1.5 times – but it is in fact the case that for three 
products, Ghanaian prices are lower than those in India. These include 
diazepam and paracetamol, which are products reserved for local manu-
facturers. Thus Table 6.4 suggests that local production in Ghana has 
contributed to affordability. 
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 If the number of products on the banned list is increased, and if free 
flow of imports into the economy is controlled, then not only will 
domestic producers find a larger market. Import restrictions may also 
induce foreign firms exporting to the country to undertake manufac-
turing within the country. 
 Table 6.4  Comparison of retail formulations prices in India and Ghana 
India: Median 
price in INR 
(1 tablet) 2013
Ghana: Median 





 Tablets manufactured in Ghana 
1. Ciprofloxacin, 500 mg 6.18 9.11 1.5
2. Amlodipine, 5 mg 2.36 3.64 1.5
3. Metformin, 500 mg 1.46 1.52 1.0
4. Diazepam, 5 mg 2.90 0.30 0.1
5. Paracetamol, 500 mg 1.14 0.30 0.3
6. Diclofenac, 50 mg 1.43 1.82 1.3
7. Lisinopril, 5 mg 4.58 6.07 1.3
8. Atorvastatin, 10 mg 8.60 9.11 1.1
9. Cetirizine Hcl, 10 mg 3.10 3.04 1.0
10. Metronidazole, 200 mg 0.39 0.61 1.6
 Tablets not yet manufactured in Ghana 
1. Anastrazole, 1 mg 48.50 182.10 3.8
2. Cepacitabine, 500 mg 150.05 267.08 1.8
3. Granisetron, 1 mg 14.05 409.73 29.2
4. Itraconazole, 100 mg 47.50 182.10 3.8
5. Losartan, 50 mg 5.65 12.14 2.1
6. Rabeprazole, 20 mg 2.75 75.88 27.6
7. Risperidone, 2 mg 3.80 75.88 20.0
8. Rosuvastatin, 20 mg 20.36 69.81 3.4
9. Tindazole, 500 mg 5.52 69.81 12.7
10. Sertraline, 100 mg 6.3 98.64 15.7
 Sources : 1. For Indian prices in col (2): median prices of retail brands accounting for 1% 
or more of the market. Market share data have been obtained from the  Sales audit data of 
AIOCD Pharmasofttech AWACS Pvt. Ltd (AIOCD-AWACS), a pharmaceutical market research 
company; Price data have been obtained from CIMS (2013). 
2. For Ghana prices in col (3): ‘Medicines List’, February 2011 of the Ghana National Health 
Insurance Scheme ( http://www.nhis.gov.gh/_Uploads/dbsAttachedFiles/1(3).pdf ). Prices in 
Ghana cedis (GHC) have been converted to Indian rupee (INR) using the annual average 
exchange rates for 2011 from  www.oanda.com . The list specifies the maximum prices at 
which the medicines purchased at the retail level are reimbursable. Pricing data are collected 
from manufacturers, wholesale distributors, private pharmacies, government, mission and 
private health facilities and the median prices are set as the maximum price reimbursable 
under the insurance scheme. 
3. Since the Ghana prices refer to 2011 whereas the Indian prices refer to 2013, depending on 
the extent to which Ghana prices have gone up since 2011, the price differential in fact may 
be larger than the figures show. 
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 Imports can also be controlled in several other ways. Ghana has 
introduced a National Health Insurance Scheme (NHIS), which covers 
about half the population. About 40% of the funds paid out by health 
insurance are for medicines. The NHIS-funded formulations market has 
therefore emerged as a major market segment in Ghana accounting for 
about 23% of the market (Seiter and Gyansa-Lutterodt, 2009: 19). The 
NHIS has expanded since that 2009 study, and the share of insurance-
funded medicine purchase has risen. The substantial bargaining power 
of the NHIS agency can thus be used to enlarge the domestic market. The 
NHIS does not currently differentiate in its procurement between medi-
cines according to whether they are manufactured locally or imported. 
However, after allowing some time for capacities to develop, NHIS reim-
bursement could be restricted to locally manufactured products. Since 
the prices to be reimbursed are being fixed by NHIS in any case, the 
possibility of such actions leading to higher prices will not arise. 
 A further policy option available is to use the instrument of govern-
ment procurement. So far as the institutional market is concerned, the 
only benefit the local manufacturers receive is the 15% price preference, 
and that too, as noted above, does not operate properly. An important 
flexibility that the World Trade Organization (WTO) provides concerns 
public procurement. The WTO Agreement on Government Procurement 
(GPA) is a plurilateral agreement which is applicable only to the member 
countries which have signed the GPA. African countries, including 
Ghana, have not yet joined the GPA. 7 
 Public procurement of drugs (and other goods) in Ghana is currently 
guided by the provisions of the Public Procurement Act. This provides 
for three types of competitive tendering: international, national and 
restricted. ‘International tendering’ means that organizations responding 
need not necessarily be located in Ghana. ‘National tendering’ means 
that the tendering can be restricted to organizations located in Ghana, 
but the organizations need not be manufacturers. They can be importers 
located in Ghana. 
 A simple step that could be initiated in Ghana for the further develop-
ment of the pharmaceutical industry is to introduce tendering restricted 
to local manufacturers. This might be a two-stage tendering process: a 
technical evaluation and then evaluation of the financial bid. At the 
first stage of technical evaluation, tenders may be accepted only from 
those local manufacturers that are GMP-compliant and that have the 
manufacturing capacities to satisfy the procurement requirements. 
The financial bid may be restricted to the companies which qualify 
in the technical evaluation. Based on the widely used International 
Reference Prices, 8 maximum purchase prices may be also specified. This 
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will ensure a larger domestic market for local manufacturers, and hence 
a more attractive market for FDI, without compromising on prices. 
 Conclusion 
 This chapter can be appropriately concluded with a quotation from the 
Chairman of an Indian company currently exporting pharmaceuticals to 
Africa. He summarized the prospects of FDI in Africa. He told us during 
an interview that if imported products including those from India are 
freely available in Africa, then it is difficult to induce Indian companies 
to go to Africa and set up plants. But if local production is somewhat 
protected, and if this is supplemented with few steps to take care of the 
disadvantages of local production in Africa including some incentives, 
for example some income tax benefits particularly in initial years and 
infrastructure support (land, water, roads, electricity), then the prospects 
of FDI from India will be brighter. In fact, his company will be willing to 
explore the possibility actively. 
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